The U.S. Food and Drug Administration approved the drug Sunitinib (marketed as Sutent) to treat patients with kidney cancer who are at high risk for tumor recurrence. Dr. Allan Pantuck, head of the UCLA Institute of Urologic Oncology’s Clinical Research Program, served on the Global Advisory Steering Committee that oversaw the conduct and progress of a clinical study of sunitinib and helped to present these findings to the FDA’s Oncologic Drugs Advisory Committee.
The OLYMPUS Study - Optimized Delivery of Mitomycin for Primary UTUC Study
The purpose of this research study is to test the ability of UroGen’s MitoGel™ procedure to treat urothelial carcinoma tumors from the upper urinary tract. View Clinical Trial >
Targeted Treatment of Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to see if the study drug, Trametinib, is safe and effective for the treatment of metastatic castration-resistant prostate cancer. View Clinical Trial >
Study Shows Multimodal Approach Improves Survival in Aggressive Prostate Cancer
The study, led by UCLA researcher Dr. Amar Kishan, shows that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer.